Australian health authorities have issued an urgent public health warning after confirming that counterfeit rabies vaccines were circulating in India, potentially leaving thousands of people without protection against a fatal disease. The alert advises travellers who received the rabies vaccine Abhayrab in India from November 1, 2023, onwards to consider themselves at risk and seek revaccination. The warning reflects growing concern that fake vaccines, which may be chemically ineffective despite appearing legitimate, could undermine rabies prevention efforts and place lives in danger long after individuals believe they are protected.
The advisory was issued jointly by the Australian Technical Advisory Group on Immunisation and multiple state health departments, following investigations that traced the circulation of counterfeit vaccine batches in several Indian cities. Australian officials have emphasised that rabies is almost always fatal once symptoms appear, making reliable vaccination critical. Because it is not possible for patients or even healthcare providers to reliably distinguish genuine vials from counterfeit ones, authorities have taken the precautionary step of treating any Abhayrab doses administered in India during the identified risk period as potentially invalid.
Discovery of counterfeit Abhayrab vaccines and the scope of the public health concern
The issue first came to light in early 2025, when Indian Immunologicals Limited, the manufacturer of Abhayrab, detected counterfeit versions of the vaccine circulating in the market. Internal checks and follow-up investigations revealed that the fake products were designed to closely mimic the genuine vaccine, including the use of authentic batch numbers. One such batch number, KA24014, was found to be fraudulently replicated, making detection particularly challenging for distributors, clinicians, and patients.
Abhayrab is a rabies vaccine that has been prequalified for use by international health authorities and is widely used for both pre-exposure and post-exposure prophylaxis. In its genuine form, it meets global standards for safety and efficacy. However, laboratory analysis of the counterfeit vials showed significant differences in chemical composition, packaging quality, and labelling details. These discrepancies raised serious doubts about whether the fake vaccines contained the necessary active ingredients to stimulate immunity against the rabies virus.
Investigators identified confirmed cases of counterfeit Abhayrab vials in major Indian cities, including Delhi, Mumbai, Ahmedabad, and Lucknow. Health officials cautioned that these findings likely represent only a portion of the actual spread, as the counterfeit supply chain may extend to other regions and healthcare facilities. The use of genuine-looking labels and batch numbers suggests a sophisticated operation capable of infiltrating legitimate distribution channels.
Australian health authorities highlighted that the risk is particularly severe because rabies vaccination is often administered following animal bites or potential exposure. Individuals who believe they are protected may delay or forgo further medical care, assuming the vaccine has provided immunity. If the administered dose was counterfeit, such delays could prove fatal. This risk prompted Australian officials to issue a broad and precautionary advisory rather than attempting to narrow the warning to specific locations or clinics.
The advisory states that any traveller vaccinated with Abhayrab in India from November 1, 2023, onwards should assume there is a possibility the vaccine was ineffective. Because it is impossible to confirm retrospectively whether a specific dose was genuine, revaccination is being recommended as the safest course of action. Health authorities stressed that this approach prioritises safety, given the high mortality rate associated with rabies and the absence of effective treatment once symptoms develop.
Guidance for travellers, revaccination advice, and broader implications for vaccine safety
In response to the discovery, Australian authorities have urged travellers who may have been affected to consult healthcare professionals promptly. Revaccination is being recommended regardless of whether individuals completed a full course of rabies vaccination in India during the risk period. For those who were vaccinated as part of post-exposure treatment after an animal bite, the advice is particularly urgent, as any lapse in protection could have serious consequences.
Health officials explained that revaccination protocols would depend on individual circumstances, including prior vaccination history, timing, and potential exposure. In some cases, blood tests may be used to assess antibody levels, but authorities noted that relying solely on serological testing may not provide complete reassurance. As a result, revaccination is being presented as the most reliable method to ensure protection.
The alert also carries broader implications for international travel and vaccine safety. Rabies remains endemic in many parts of the world, including India, and travellers often rely on local healthcare facilities for urgent post-exposure care. The circulation of counterfeit vaccines undermines confidence in these systems and highlights vulnerabilities in pharmaceutical supply chains. Australian authorities emphasised that the warning is not an indictment of vaccination programmes as a whole, but a targeted response to a specific and serious breach in vaccine integrity.
Australian health departments have also advised clinicians to take detailed vaccination histories from patients who have recently travelled to India and to consider the possibility of counterfeit exposure when assessing rabies risk. Medical professionals have been asked to report suspected cases and to follow updated guidance on revaccination and patient counselling. Clear communication with affected individuals is being encouraged to prevent panic while ensuring timely protective measures.
The discovery of counterfeit Abhayrab vaccines has prompted renewed discussion about the need for stronger oversight, verification mechanisms, and international cooperation to combat pharmaceutical fraud. Counterfeit medicines pose a global health threat, particularly when they involve vaccines or life-saving treatments. Health experts warn that such products not only endanger individual patients but also erode trust in public health systems and immunisation programmes.
Australian authorities noted that rabies prevention depends on a chain of trust that includes manufacturers, distributors, healthcare providers, and regulators. When any link in that chain is compromised, the consequences can be severe. The current advisory reflects an effort to mitigate harm after the fact, but officials have stressed the importance of preventive measures to stop counterfeit products from entering the market in the first place.
While the immediate focus of the alert is on protecting travellers and ensuring they receive effective vaccination, the situation also serves as a cautionary example for global health systems. The ability of counterfeit vaccines to circulate undetected for months underscores the need for improved surveillance, better authentication technologies, and rapid information sharing between countries.
Australian health authorities have reiterated that rabies is preventable with timely and effective vaccination, and that the current warning should be seen as a proactive step to safeguard public health. By advising revaccination and raising awareness of the counterfeit risk, they aim to ensure that individuals who may have been exposed are not left with a false sense of security. The alert stands as a reminder that vigilance remains essential in the fight against both infectious diseases and the counterfeit products that threaten efforts to control them.
